CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

SYK-dependent signals from the pre-BCR then feed into the PI3K pathway through CD19 and/or BCAP ... different FOXO family members in B-cell development and function has to be investigated.

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...

SynKIR-310 targets CD19, which is a common target in approved CAR T therapies with the potential for “prolonged anti-tumour T cell function and persistence”. A multi-chain CAR T cell therapy ...